Core Viewpoint - The stock of Innovent Biologics (09969) has risen over 6%, currently trading at 18.87 HKD, following the announcement of its innovative drug, Tafasitamab, entering clinical application in China [1] Group 1: Company Developments - Innovent Biologics has announced that Tafasitamab, a CD19 monoclonal antibody, has received its first prescriptions in multiple provinces across China, including Beijing, Shanghai, Guangdong, and others [1] - Tafasitamab is the first and only CD19 monoclonal antibody approved for the treatment of lymphoma globally, and it is also the first approved treatment for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in China [1] - The introduction of Tafasitamab fills a significant gap in CD19 targeted therapy in China, providing better treatment options for DLBCL patients [1]